Neratinib-Induced Duodenal Ulcer: A Case Report.
HER2
Neratinib
adjuvant
toxicity
ulcer
Journal
Breast cancer : basic and clinical research
ISSN: 1178-2234
Titre abrégé: Breast Cancer (Auckl)
Pays: United States
ID NLM: 101474356
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
05
2020
accepted:
27
05
2020
entrez:
9
7
2020
pubmed:
9
7
2020
medline:
9
7
2020
Statut:
epublish
Résumé
We report a case of a 37-year-old woman who developed a duodenal ulcer while receiving adjuvant neratinib for HER2 positive breast cancer. The clinical course of abdominal pain was strongly correlated with the use of neratinib. An esophagogastroduodenoscopy (EGD) was performed and confirmed the diagnosis of a large duodenal ulcer. Neratinib was stopped, and the patient was treated with a proton pump inhibitor. Repeat EGD performed 3 months later showed complete resolution of the duodenal ulcer. Given this unexpected serious adverse event and only modest benefit of neratinib in the adjuvant setting, the decision was made to forgo further treatment with neratinib. Physicians should be aware of the gastrointestinal (GI) side effects associated with neratinib and recognize that peptic ulcer disease may be another GI toxicity associated with neratinib use.
Identifiants
pubmed: 32636634
doi: 10.1177/1178223420935871
pii: 10.1177_1178223420935871
pmc: PMC7315670
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1178223420935871Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Declaration of Conflicting Interests:The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Moftakhar: No COI. Kharel: No COI. Niraula: No COI. Gandhi: Roswell Park Alliance Foundation. Falkson: Have received research funding from Roche, Genentech, Novartis, Seattle Genetics, Pfizer, and Lily at her prior institution. Dhakal: Have received an honorarium from Daichii Sankyo.
Références
Br J Clin Pharmacol. 2017 Mar;83(3):554-561
pubmed: 27628584
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
Lancet Oncol. 2016 Mar;17(3):367-377
pubmed: 26874901
J Clin Oncol. 2019 May 1;37(13):1081-1089
pubmed: 30860945
Expert Opin Drug Saf. 2017 Oct;16(10):1111-1119
pubmed: 28766379
J Clin Oncol. 2014 Jan 10;32(2):68-75
pubmed: 24323026
JAMA Oncol. 2016 Dec 1;2(12):1557-1564
pubmed: 27078022
Clin Cancer Res. 2009 Apr 1;15(7):2552-8
pubmed: 19318484
Clin Cancer Res. 2017 Oct 1;23(19):5687-5695
pubmed: 28679771
Lancet Oncol. 2017 Dec;18(12):1688-1700
pubmed: 29146401
Clin Drug Investig. 2019 Jan;39(1):27-43
pubmed: 30370488
J Clin Oncol. 2010 Mar 10;28(8):1301-7
pubmed: 20142587
Cancer Chemother Pharmacol. 2019 Feb;83(2):329-340
pubmed: 30467591
N Engl J Med. 2016 Jul 7;375(1):11-22
pubmed: 27406346